Mercury Biopharmaceutical Corporation (TPEX:6932)

Mercury Biopharmaceutical Revenue

In the year 2024, Mercury Biopharmaceutical had annual revenue of 4.96M TWD with 380.45% growth. Mercury Biopharmaceutical had revenue of 246.00K in the half year ending December 31, 2024, a decrease of -90.82%.

• Revenue: 4.96M
• Revenue Growth: +380.45%
• P/S Ratio: 754.78
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 3.75B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	4.96M	3.93M	380.45%
Dec 31, 2023	1.03M	-1.65M	-61.46%
Dec 31, 2022	2.68M	-	-
Dec 31, 2021	-	-	-
Dec 31, 2020	-	-	-